Velour trial biomarkers update: Impact of RAS, BRAF, and sidedness on aflibercept activity.

Pratyaksha Wirapati,Valentina Pomella,Ben Vandenbosch,Peter Kerr,Evaristo Maiello,Grahame Mark Jeffery,Razvan-Ovidiu D. Curca,Meinolf Karthaus,John Bridgewater,Anca C. Mihailov,Igor Kiss,Sandra Merino,Joseph McKendrick,Zacharenia Saridaki,Xavier Sagaert,Sabine Tejpar

Velour trial biomarkers update: Impact of RAS, BRAF, and sidedness on aflibercept activity.

2017

Pratyaksha Wirapati
Valentina Pomella
Ben Vandenbosch
Peter Kerr
Evaristo Maiello
Grahame Mark Jeffery
Razvan-Ovidiu D. Curca
Meinolf Karthaus
John Bridgewater
Anca C. Mihailov
Igor Kiss
Sandra Merino
Joseph McKendrick
Zacharenia Saridaki
Xavier Sagaert
Sabine Tejpar

3538Background: Addition of (ziv)-aflibercept (A) to FOLFIRI in second-line therapy for metastatic colorectal cancer (CRC) has been shown to be beneficial in phase III VELOUR trial (NCT00561470). A...

Keywords:

Biomarker (medicine)
Colorectal cancer
Aflibercept
Medicine
Oncology
Internal medicine
FOLFIRI

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations